Morepen Laboratories Limited (BOM:500288)
India · Delayed Price · Currency is INR 92.00
-4.80 (-4.96%)
At close: Nov 6, 2026
Morepen Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 22,855 | 18,057 | 18,116 | 16,904 | 14,175 | 15,468 |
Other Revenue | - | - | - | - | 44.76 | 89.77 |
| 22,855 | 18,057 | 18,116 | 16,904 | 14,220 | 15,558 | |
Revenue Growth | 30.20% | -0.33% | 7.17% | 18.88% | -8.60% | 29.87% |
Cost of Revenue | 13,337 | 11,484 | 11,854 | 10,858 | 9,750 | 10,611 |
Gross Profit | 9,518 | 6,572 | 6,262 | 6,047 | 4,470 | 4,947 |
Selling, General & Admin | 3,576 | 2,383 | 2,118 | 1,935 | 1,654 | 1,724 |
Other Operating Expenses | 3,178 | 2,934 | 2,403 | 2,525 | 1,976 | 1,766 |
Operating Expenses | 7,099 | 5,681 | 4,811 | 4,795 | 3,910 | 3,767 |
Operating Income | 2,419 | 891.94 | 1,451 | 1,252 | 560.79 | 1,180 |
Interest Expense | -178.9 | -160.74 | -77.85 | -37.1 | -19.81 | -24.26 |
Interest & Investment Income | 16.94 | 16.94 | 48.15 | 25.04 | 16.57 | 13.3 |
Currency Exchange Gain (Loss) | 179.26 | 179.26 | 102.95 | 96.97 | - | - |
Other Non Operating Income (Expenses) | 61.8 | 13.56 | 26.97 | 17.7 | - | 97.92 |
EBT Excluding Unusual Items | 2,498 | 940.95 | 1,551 | 1,354 | 557.55 | 1,267 |
Other Unusual Items | - | 258.25 | - | - | - | - |
Pretax Income | 2,498 | 1,199 | 1,551 | 1,354 | 557.55 | 1,267 |
Income Tax Expense | 613.43 | 242.74 | 370.94 | 387.95 | 170.8 | 250.21 |
Earnings From Continuing Operations | 1,884 | 956.47 | 1,180 | 966.2 | 386.76 | 1,017 |
Minority Interest in Earnings | -16.54 | -7.7 | 0.05 | -4.6 | -0 | 0.01 |
Net Income | 1,868 | 948.77 | 1,180 | 961.6 | 386.75 | 1,017 |
Net Income to Common | 1,868 | 948.77 | 1,180 | 961.6 | 386.75 | 1,017 |
Net Income Growth | 86.26% | -19.61% | 22.73% | 148.64% | -61.97% | 4.74% |
Shares Outstanding (Basic) | 541 | 548 | 535 | 511 | 502 | 450 |
Shares Outstanding (Diluted) | 541 | 548 | 535 | 511 | 502 | 520 |
Shares Change | -2.36% | 2.37% | 4.71% | 1.79% | -3.39% | 15.24% |
EPS (Basic) | 3.45 | 1.73 | 2.20 | 1.88 | 0.77 | 2.26 |
EPS (Diluted) | 3.45 | 1.73 | 2.20 | 1.88 | 0.77 | 1.96 |
EPS Growth | 91.27% | -21.47% | 17.28% | 144.16% | -60.71% | -8.84% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 345.3 | -528.81 | -919.76 | 19.94 | -1,268 | -1,057 |
Free Cash Flow Per Share | 0.64 | -0.96 | -1.72 | 0.04 | -2.52 | -2.03 |
Dividend Per Share | - | 0.200 | 0.200 | - | - | - |
Dividend Growth | - | 0% | - | - | - | - |
Gross Margin | 41.64% | 36.40% | 34.57% | 35.77% | 31.44% | 31.80% |
Operating Margin | 10.58% | 4.94% | 8.01% | 7.40% | 3.94% | 7.58% |
Profit Margin | 8.17% | 5.25% | 6.51% | 5.69% | 2.72% | 6.54% |
Free Cash Flow Margin | 1.51% | -2.93% | -5.08% | 0.12% | -8.92% | -6.79% |
EBITDA | 2,609 | 1,101 | 1,623 | 1,586 | 840.09 | 1,456 |
EBITDA Margin | 11.41% | 6.10% | 8.96% | 9.38% | 5.91% | 9.36% |
D&A For EBITDA | 189.93 | 208.81 | 171.82 | 334.7 | 279.3 | 276.43 |
EBIT | 2,419 | 891.94 | 1,451 | 1,252 | 560.79 | 1,180 |
EBIT Margin | 10.58% | 4.94% | 8.01% | 7.40% | 3.94% | 7.58% |
Effective Tax Rate | 24.56% | 20.24% | 23.91% | 28.65% | 30.63% | 19.75% |
Revenue as Reported | 23,116 | 18,270 | 18,299 | 17,044 | 14,237 | 15,571 |